-+ 0.00%
-+ 0.00%
-+ 0.00%

C4 THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B TRIAL OF CEMSIDOMIDE IN COMBINATION WITH ELRANATAMAB (ELREXFIO®) FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

Reuters·03/25/2026 11:00:01

Please log in to view news